NCT00004873CompletedPhase 2
Taxotere-Cisplatin-5FU (TCF) Versus Taxotere-Cisplatin (TC) Versus Epirubicin-Cisplatin-5FU (ECF) as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Swiss Cancer Institute
- Locations
- 2
Study Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating advanced stomach cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of different regimens of combination chemotherapy in treating patients who have advanced stomach cancer.
Detailed Description
OBJECTIVES:
- Compare the efficacy and tolerability of docetaxel, cisplatin, and fluorouracil (TCF) versus docetaxel and cisplatin (TC) versus epirubicin, cisplatin, and fluorouracil (ECF) in patients with advanced gastric carcinoma.
- Compare the time to treatment failure, time to progression, and survival in this patient population treated with these regimens.
- Compare the quality of life during the treatment period and after failure in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, performance status (0 vs 1), and liver involvement (yes vs no). Patients are randomized to one of three treatment arms.
- Arm I: Patients receive epirubicin IV bolus and cisplatin IV over 4 hours on day 1 plus fluorouracil IV continuously on days 1-21.
- Arm II: Patients receive docetaxel IV over 1 hour and cisplatin IV over 4 hours on day 1.
- Arm III: Patients receive docetaxel and cisplatin as in arm II and fluorouracil as in arm I.
Treatment regimen is repeated every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed gastric carcinoma not amenable to curative surgery or in relapse after primary surgical resection
- •Locally advanced disease (i.e., measurable locoregional lymph nodes) OR
- •Metastatic disease
- •Bidimensionally measurable disease
- •At least 10 mm X 20 mm by chest x-ray or physical examination
- •At least 10 mm X 10 mm by CT scan
- •No CNS metastasis
- •PATIENT CHARACTERISTICS:
- •Performance status:
- •Life expectancy:
- •Greater than 12 weeks
- •Hematopoietic:
- •WBC count at least 4,000/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin no greater than 1.25 times upper limit of normal (ULN)
- •AST/ALT no greater than 2.5 times ULN
- •Alkaline phosphatase no greater than 5 times ULN
- •BUN normal
- •Creatinine normal
- •Creatinine clearance at least 60 mL/min
- •No severe hypercalcemia
- •Cardiovascular:
- •No unstable cardiac disease requiring treatment
- •No congestive heart failure
- •No angina pectoris even if medically controlled
- •No significant arrhythmias
- •No prior myocardial infarction unless ejection fraction at least 50% by MUGA scan or echocardiogram
- •Neurologic:
- •No prior significant neurologic or psychiatric disorders, including psychotic disorders, dementia or seizures that would preclude study
- •No peripheral neuropathy of any origin (alcohol, etc.) greater than grade 1
- •Fertile patients must use adequate contraception
- •No prior malignancy except basal cell skin cancer or adequately treated carcinoma in situ of the cervix
- •No active uncontrolled infection
- •No other serious illness or medical condition that would preclude study participation
- •No contraindication to corticosteroid use
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •No prior palliative chemotherapy
- •At least 12 months since prior adjuvant or neoadjuvant chemotherapy
- •No prior taxanes
- •Prior fluorouracil allowed in bolus form only
- •Prior cumulative dose of adjuvant or neoadjuvant cisplatin no greater than 300 mg/m2
- •Endocrine therapy:
- •Prior or concurrent prednisone (or equivalent) allowed for prophylaxis, acute hypersensitivity reactions, or chronic therapy (greater than 6 months) at doses no greater than 20 mg
- •Radiotherapy:
- •Not specified
- •See Disease Characteristics
- +3 more not shown
Exclusion Criteria
- Not provided
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung CancerLung CancerNCT00005868European Organisation for Research and Treatment of Cancer - EORTC47
Completed
Phase 2
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With SurgeryBreast CancerNCT00015886Wake Forest University Health Sciences25
Completed
Phase 3
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerFallopian Tube CancerPeritoneal Cavity CancerOvarian CancerNCT00028743NCIC Clinical Trials Group819
Completed
Phase 3
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the PleuraMalignant MesotheliomaNCT00004920European Organisation for Research and Treatment of Cancer - EORTC256
Completed
Phase 3
Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the PancreasPancreatic CancerNCT00003029European Organisation for Research and Treatment of Cancer - EORTC200